As its oncology effort gathers steam, AstraZeneca sheds another legacy drug

On the day AstraZeneca suffered a setback after the US regulator rejected its triplet for chronic obstructive pulmonary disease — it also palmed off the rights to a legacy treatment, Losec, to Germany’s Cheplapharm Arzneimittel GmbH in a deal worth $243 million upfront.